IIC
INSY

Integrated Investment Consultants’s Insys Therapeutics, Inc. INSY Stock Holding History

Integrated Investment Consultants’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-80
Closed – – 805
2018
Q1 		$0 Buy
+80
New +$661 ﹤0.01% 844
2017
Q3 		$1K Hold
80
– – ﹤0.01% 638
2017
Q2 		$1K Hold
80
– – ﹤0.01% 584
2017
Q1 		$1K Buy
+80
New +$852 ﹤0.01% 577

Other funds holding INSY

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Integrated Investment Consultants's INSY Position: Q2 2018 in Review

Integrated Investment Consultants sold out of Insys Therapeutics, Inc. (INSY) in Q2 2018, closing a stake of 80 shares.

Integrated Investment Consultants first reported a position in INSY in Q1 2017 and held it in 4 quarters. The position peaked at $1K in Q3 2017. 103 funds tracked by Wall St. Rank hold INSY as of Q2 2018.

  • Integrated Investment Consultants reported no remaining Insys Therapeutics, Inc. position as of Q2 2018 after selling out during the quarter.
  • Integrated Investment Consultants sold 80 Insys Therapeutics, Inc. shares in Q2 2018.
  • Integrated Investment Consultants first reported a position in Insys Therapeutics, Inc. in Q1 2017 and held it in 4 quarters.
  • Integrated Investment Consultants's Insys Therapeutics, Inc. position peaked at $1K in Q3 2017.
  • 103 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q2 2018.

Based on Integrated Investment Consultants's 13F filing for Q2 2018, filed 1 Aug 2018.